ArticleJournal of Cancer2021

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study.

Li Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.